Protagenic Therapeutics enters ATM sales agreement for up to $1.2M with B. Riley Securities

Protagenic Therapeutics, Inc.new

Amendment No. 1 to At Market Issuance Sales Agreement with B. Riley Securities, dated Jan 9, 2025.
Company may sell up to $1.2 million of common stock from time to time in at-the-market offerings.
Agent commission is 3.0% of gross sales price; Company can terminate agreement on notice.
Sales will be made under effective shelf registration statement (333-280244), declared effective Jan 8, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.